New drugs for the treatment of myelofibrosis

Ruben A. Mesa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Managing patients with myelofibrosis (MF)-either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential thrombocythemia-presents many challenges to the hematologist. Cure is potentially achievable through allogeneic stem cell transplantation, but this therapy is either inappropriate or not feasible for most patients. MF patients suffer from a range of debilitating disease manifestations (eg, massive splenomegaly, cytopenias, constitutional symptoms, and transformation to a treatment-refractory blast phase). Currently available therapies are palliative but can be of significant value to some MF patients for anemia, splenomegaly, or sometimes both manifestations. New medical therapies for MF revolve around three main themes: immunomodulation (to assist anemia), hypomethylation strategies, and (the most robust pipeline) the use of targeted JAK2 inhibitors. These latter agents have shown the ability to improve MF-associated splenomegaly and MF-associated symptoms but do not improve (and may exacerbate) anemia or thrombocytopenia. Future targeted agents, and perhaps combinations of agents that currently show complementary benefits, are anticipated to further enhance the efficacy of medical therapy for MF.

Original languageEnglish (US)
Pages (from-to)15-21
Number of pages7
JournalCurrent Hematologic Malignancy Reports
Volume5
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Primary Myelofibrosis
Pharmaceutical Preparations
Splenomegaly
Anemia
Therapeutics
Blast Crisis
Essential Thrombocythemia
Polycythemia Vera
Immunomodulation
Stem Cell Transplantation
Cell- and Tissue-Based Therapy
Palliative Care
Thrombocytopenia

Keywords

  • JAK2
  • Myelofibrosis
  • Myeloproliferative disorder

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

New drugs for the treatment of myelofibrosis. / Mesa, Ruben A.

In: Current Hematologic Malignancy Reports, Vol. 5, No. 1, 01.2010, p. 15-21.

Research output: Contribution to journalArticle

Mesa, Ruben A. / New drugs for the treatment of myelofibrosis. In: Current Hematologic Malignancy Reports. 2010 ; Vol. 5, No. 1. pp. 15-21.
@article{ec9d3a04aef042fba2174ae3bb168d75,
title = "New drugs for the treatment of myelofibrosis",
abstract = "Managing patients with myelofibrosis (MF)-either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential thrombocythemia-presents many challenges to the hematologist. Cure is potentially achievable through allogeneic stem cell transplantation, but this therapy is either inappropriate or not feasible for most patients. MF patients suffer from a range of debilitating disease manifestations (eg, massive splenomegaly, cytopenias, constitutional symptoms, and transformation to a treatment-refractory blast phase). Currently available therapies are palliative but can be of significant value to some MF patients for anemia, splenomegaly, or sometimes both manifestations. New medical therapies for MF revolve around three main themes: immunomodulation (to assist anemia), hypomethylation strategies, and (the most robust pipeline) the use of targeted JAK2 inhibitors. These latter agents have shown the ability to improve MF-associated splenomegaly and MF-associated symptoms but do not improve (and may exacerbate) anemia or thrombocytopenia. Future targeted agents, and perhaps combinations of agents that currently show complementary benefits, are anticipated to further enhance the efficacy of medical therapy for MF.",
keywords = "JAK2, Myelofibrosis, Myeloproliferative disorder",
author = "Mesa, {Ruben A.}",
year = "2010",
month = "1",
doi = "10.1007/s11899-009-0037-y",
language = "English (US)",
volume = "5",
pages = "15--21",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - New drugs for the treatment of myelofibrosis

AU - Mesa, Ruben A.

PY - 2010/1

Y1 - 2010/1

N2 - Managing patients with myelofibrosis (MF)-either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential thrombocythemia-presents many challenges to the hematologist. Cure is potentially achievable through allogeneic stem cell transplantation, but this therapy is either inappropriate or not feasible for most patients. MF patients suffer from a range of debilitating disease manifestations (eg, massive splenomegaly, cytopenias, constitutional symptoms, and transformation to a treatment-refractory blast phase). Currently available therapies are palliative but can be of significant value to some MF patients for anemia, splenomegaly, or sometimes both manifestations. New medical therapies for MF revolve around three main themes: immunomodulation (to assist anemia), hypomethylation strategies, and (the most robust pipeline) the use of targeted JAK2 inhibitors. These latter agents have shown the ability to improve MF-associated splenomegaly and MF-associated symptoms but do not improve (and may exacerbate) anemia or thrombocytopenia. Future targeted agents, and perhaps combinations of agents that currently show complementary benefits, are anticipated to further enhance the efficacy of medical therapy for MF.

AB - Managing patients with myelofibrosis (MF)-either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential thrombocythemia-presents many challenges to the hematologist. Cure is potentially achievable through allogeneic stem cell transplantation, but this therapy is either inappropriate or not feasible for most patients. MF patients suffer from a range of debilitating disease manifestations (eg, massive splenomegaly, cytopenias, constitutional symptoms, and transformation to a treatment-refractory blast phase). Currently available therapies are palliative but can be of significant value to some MF patients for anemia, splenomegaly, or sometimes both manifestations. New medical therapies for MF revolve around three main themes: immunomodulation (to assist anemia), hypomethylation strategies, and (the most robust pipeline) the use of targeted JAK2 inhibitors. These latter agents have shown the ability to improve MF-associated splenomegaly and MF-associated symptoms but do not improve (and may exacerbate) anemia or thrombocytopenia. Future targeted agents, and perhaps combinations of agents that currently show complementary benefits, are anticipated to further enhance the efficacy of medical therapy for MF.

KW - JAK2

KW - Myelofibrosis

KW - Myeloproliferative disorder

UR - http://www.scopus.com/inward/record.url?scp=76649136120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649136120&partnerID=8YFLogxK

U2 - 10.1007/s11899-009-0037-y

DO - 10.1007/s11899-009-0037-y

M3 - Article

C2 - 20425392

AN - SCOPUS:76649136120

VL - 5

SP - 15

EP - 21

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 1

ER -